RUA Life Sciences PLC Result of AGM (8103V)

TIDMRUA

RNS Number : 8103V

RUA Life Sciences PLC

11 August 2020

RUA Life Sciences Plc

("RUA Life Sciences", the "Company" or the "Group")

Result of AGM

RUA Life Sciences, the holding company of a group of medical device businesses focused on the exploitation of the world's leading long-term implantable biostable polymer (Elast-Eon(TM) ), announces that all resolutions put to shareholders at its Annual General Meeting held earlier today, were duly passed.

For further information contact:

RUA Life Sciences

   Bill Brown, Chairman                       Tel: [phone] 
   David Richmond, CEO                     Tel: [phone] 

Shore Capital

   Tom Griffiths/David Coaten              Tel: [phone] 

About RUA Life Sciences

The RUA Life Sciences group was created in April 2020 when RUA Life Sciences Plc (formerly known as AorTech International Plc) acquired RUA Medical Devices Limited to create a fully formed medical device business. RUA Life Sciences is the holding company of the Group's four trading businesses, each exploiting the Group's patented polymer technology.

Our vision is to improve the lives of millions of patients by improving and enabling medical devices with Elast-Eon(TM) , the world's leading long-term implantable polyurethane.

Whether it is licensing Elast-Eon(TM) , manufacturing a device or component or developing next generation medical devices, a RUA Life Sciences business is pursuing our vision.

Elast-Eon(TM)'s biostability is comparable to silicone while exhibiting excellent mechanical, blood contacting and flex-fatigue properties. These polymers can be processed using conventional thermoplastic extrusion and moulding techniques. With over 7 million implants and over 14 years of successful clinical use, RUA's polymers are proven in long-term life enabling applications.

The Group's four business units are:

 
 RUA Medical        End-to-end contract developer and manufacturer 
  :                  of medical devices and implantable fabric 
                     specialist. 
 RUA Biomaterials   Licensor of Elast-Eon(TM) polymers to the 
  :                  medical device industry. 
 RUA Vascular:      Commercialisation of large bore polymer sealed 
                     grafts and soft tissue patches. 
 RUA Structural     Development of tri leaflet polymeric heart 
  Heart :            valves. 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

RAGPBMBTMTMBBTM

(END) Dow Jones Newswires

August 11, 2020 07:04 ET (11:04 GMT)